Previous 10 | Next 10 |
Image source: The Motley Fool. Paratek Pharmaceuticals (NASDAQ: PRTK) Q4 2020 Earnings Call Feb 24, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Paratek Pharmaceuticals (PRTK) Q4 2020 Earnings Call Transcript
Paratek Pharmaceuticals, Inc. (PRTK) Q4 2020 Earnings Conference Call February 24, 2021 4:30 PM ET Company Participants Ben Strain - Vice President of Investor Relations Evan Loh - Chief Executive Officer Adam Woodrow - President and Chief Commercial Officer Randy Brenner - Chief Development ...
The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Paratek Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
Paratek Pharmaceuticals (PRTK): Q4 GAAP EPS of -$0.54 misses by $0.45.Revenue of $16.02M (+78.6% Y/Y) misses by $18.02M.2021 Guidance: Total revenue of $166 to $177M; NUZYRA net U.S. product sales ~$138 to $144M; U.S. net product sales $62 to $68M;...
-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 -- NUZYRA Expansion into the Primary Care Setting in 2021 -- Paratek Expects Full Year 2021 Total Revenue Between $166 and $177 Mi...
BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, go...
BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company that develops and commercializes life-saving therapies for public health threats in the community, hospital, and military settings, today announced the expansion of the Compan...
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments. Ocumension Therapeutics inv...
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...
News, Short Squeeze, Breakout and More Instantly...
Paratek Pharmaceuticals Inc. Company Name:
PRTK Stock Symbol:
NASDAQ Market:
Paratek Pharmaceuticals Inc. Website:
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Paratek Pharmaceuticals Inc. (PRTK) is expected to report $-0.25 for Q3 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military ...